Wang Bingrui, Wang Chenchen, Wan Yang, Gao Jie, Ma Yige, Zhang Yingnan, Tong Jingyuan, Zhang Yingchi, Liu Jinhua, Chang Lixian, Xu Changlu, Shen Biao, Chen Yumei, Jiang Erlie, Kurita Ryo, Nakamura Yukio, Lim Kim-Chew, Engel James Douglas, Zhou Jiaxi, Cheng Tao, Zhu Xiaofan, Zhu Ping, Shi Lihong
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China.
Department of Stem Cell and Regenerative Medicine, Peking Union Medical College, Tianjin, China.
Cell Discov. 2022 May 10;8(1):41. doi: 10.1038/s41421-022-00389-z.
Ribosomal protein dysfunction causes diverse human diseases, including Diamond-Blackfan anemia (DBA). Despite the universal need for ribosomes in all cell types, the mechanisms underlying ribosomopathies, which are characterized by tissue-specific defects, are still poorly understood. In the present study, we analyzed the transcriptomes of single purified erythroid progenitors isolated from the bone marrow of DBA patients. These patients were categorized into untreated, glucocorticoid (GC)-responsive and GC-non-responsive groups. We found that erythroid progenitors from untreated DBA patients entered S-phase of the cell cycle under considerable duress, resulting in replication stress and the activation of P53 signaling. In contrast, cell cycle progression was inhibited through induction of the type 1 interferon pathway in treated, GC-responsive patients, but not in GC-non-responsive patients. Notably, a low dose of interferon alpha treatment stimulated the production of erythrocytes derived from DBA patients. By linking the innately shorter cell cycle of erythroid progenitors to DBA pathogenesis, we demonstrated that interferon-mediated cell cycle control underlies the clinical efficacy of glucocorticoids. Our study suggests that interferon administration may constitute a new alternative therapeutic strategy for the treatment of DBA. The trial was registered at www.chictr.org.cn as ChiCTR2000038510.
核糖体蛋白功能障碍会引发多种人类疾病,包括先天性纯红细胞再生障碍性贫血(DBA)。尽管所有细胞类型都普遍需要核糖体,但以组织特异性缺陷为特征的核糖体病的潜在机制仍知之甚少。在本研究中,我们分析了从DBA患者骨髓中分离出的单个纯化红系祖细胞的转录组。这些患者被分为未治疗组、糖皮质激素(GC)反应组和GC无反应组。我们发现,未经治疗的DBA患者的红系祖细胞在相当大的压力下进入细胞周期的S期,导致复制应激和P53信号激活。相比之下,在接受治疗的GC反应型患者中,通过诱导1型干扰素途径抑制了细胞周期进程,但在GC无反应型患者中则没有。值得注意的是,低剂量的干扰素α治疗刺激了DBA患者来源的红细胞生成。通过将红系祖细胞固有的较短细胞周期与DBA发病机制联系起来,我们证明了干扰素介导的细胞周期控制是糖皮质激素临床疗效的基础。我们的研究表明,给予干扰素可能构成一种治疗DBA的新的替代治疗策略。该试验已在www.chictr.org.cn注册,注册号为ChiCTR2000038510。